NASDAQ:BTTC Black Titan Q1 2026 Earnings Report $0.71 -0.02 (-3.23%) As of 04:00 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Black Titan EPS ResultsActual EPS-$1.81Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ABlack Titan Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ABlack Titan Announcement DetailsQuarterQ1 2026Date2/18/2026TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Black Titan Earnings HeadlinesBlack Titan Deploys Cash Reserves to Accelerate Southeast Asia ExpansionJuly 21, 2026 | tipranks.comBlack Titan Names CFO Brynner Chiam Interim Co-CEO in July 2026 Leadership ShiftJuly 13, 2026 | tipranks.comApple just sent a powerful signal to investorsApple just crossed a $5 trillion market value as shares climbed 25% this year, fueled by new product launches and rising interest in foldable phones. Mode Mobile is building on top of that ecosystem with its EarnOS platform, already serving 490M+ users across 170+ countries and generating $115M+ in lifetime revenue. Deloitte ranked Mode North America's number 1 fastest-growing software company in 2023 after 32,481% growth. Pre-IPO shares are available at $0.52 before the price changes on August 14.August 4 at 1:00 AM | Mode Mobile (Ad)Black Titan CorporationJuly 8, 2026 | cnn.comContinued Institutionalization of Crypto Payments InfrastructureJune 24, 2026 | usatoday.comBlack Titan Highlights Rising Institutional Focus on Stablecoin-Based PaymentsJune 23, 2026 | tipranks.comSee More Black Titan Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Black Titan? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Black Titan and other key companies, straight to your email. Email Address About Black TitanTitan Pharmaceuticals, Inc. is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.View Black Titan ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Grab Holdings Stock Forms Bottom After Strong Beat-and-Raise QuarterThe AI Chip Stock Making a Quiet Move Toward DominanceApple’s AI Strategy Looks Different—Will It Pay Off?Reddit’s U.S. User Decline Raises a Bigger Question After Its Earnings BeatWhy Walmart and Amazon Could Be the Market’s Most Complementary Mega-CapsMarriott’s Earnings Drop May Be Missing the Bigger Fee Growth StoryDodging Deutsche Telekom: T-Mobile's Strategic Win Upcoming Earnings DoorDash (8/5/2026)Walt Disney (8/5/2026)MercadoLibre (8/5/2026)Occidental Petroleum (8/5/2026)Phillips 66 (8/5/2026)Allstate (8/5/2026)Brookfield Asset Management (8/5/2026)MetLife (8/5/2026)Manulife Financial (8/5/2026)Block (8/5/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
